Accessibility Tools

Bedfordshire, Luton and Milton Keynes Area Prescribing Committee

Ref: APC Bulletin 242 (Last Updated February 2020)
Bulletin Date: 26/02/20
Review Date: February 2023


Bulletin 242: Low Molecular Weight Heparins (LMWHs), Fondaparinux and Novel Oral Anticoagulants – Prescribing Guidance and Responsibilities

Formulary Status - AMBER

Amber medicines are considered suitable for TP prescribing following specialist initiation.

APC Recommendations:

Aims

To support the prescribing and monitoring of treatment and prophylactic doses of LMWHs, Fondaparinux and NOACs across the primary/secondary care interface for venous thromboembolism (VTE).

To support primary care prescribers in the governance and safety of initiating and/or continuing the prescribing of these agents.

Objectives
  • Define the place in therapy of LMWH, Fondaparinux and NOACs for primary care prescribers.
  • Identify who is responsible for the initiation and continued supply (where relevant) of these agents thereby minimising confusion.
  • Ensure that these agents are used safely and appropriately across Bedfordshire and Luton CCGs.

See attached bulletin for full details 

View Document

Please use the search box to search the whole site if you can't find what you're looking for:

To top
Welcome to the BLMK Medicines Optimisation website.
This site is currently being updated.

If you have any feedback or find any issues, please email the team:
BLMKICB.MedsOpt@nhs.net